Fiji Kava (ASX:FIJ) and EVE Investments (ASX:EVE) both surged in morning trade after revealing more money would be coming their way.

Organic honey producer EVE updated shareholders on its China sales, saying that the latest shipment had been completely sold before even arriving in Shanghai.

It has also received an additional order from Yandi, its Chinese distributor, for 21,120 units of its native honey.

On top of this, the company  is expecting the first order of its Tea Tree honey product in the coming weeks following a successful test shipment a couple of months ago.

“The response to Meluka’s honey range in China and the additional re-order provides us with confidence about our strategy for the Chinese market and the Asian region,” said EVE managing director Bill Fry.

Shares in EVE rose by 33 per cent this morning.

EVE Investments (ASX:EVE) share price chart


BioCeuticals will use kava

Meanwhile, Fiji Kava announced its first collaboration to supply its kava extract under a license agreement.

Kava is a beverage made from South Pacific Island crops that is popular in easing anxiety, insomnia, and stress.

The deal comes from Blackmores (ASX:BKL) owned vitamin supplier BioCeuticals, which will have non-exclusive rights to license the use of Fiji Kava’s product in one of its anti-anxiety and stress products – AnxioCalm.

This is on top of retail agreements with Coles (ASX:COL), Green Cross Pharmacy in New Zealand, and Amazon in the United States.

“This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava,” said Fiji Kava CEO Zane Yoshida.

Fiji Kava shares also rose this morning, by over 40 per cent.

Fiji Kava (ASX:FIJ) share price chart